The Association of Lunula Status With the Efficacy and Safety of Neoadjuvant Therapy in Breast Cancer

NCT07590570 · tracked via the Priya Life Science China tracker

Sponsor

Wenjin Yin

Phase

Observational

Started

2026-05-01

Last updated

2026-05-15

Condition(s) studied

Breast Cancer Invasive

Investigational drug(s) / intervention(s)

neoadjuvant therapy

neoadjuvant therapy: patients receiving neoadjuvant therapy

Study summary

This is a multicentre study to investigate the association of fingernail lunula status with the efficacy and safety of neoadjuvant therapy in breast cancer patients.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Aged 18 years or older * Pathologically confirmed invasive primary breast cancer * Patients who have received or are scheduled to receive neoadjuvant therapy Exclusion Criteria: * De novo stage IV breast cancer

Primary outcome measure(s)

Pathological Complete Response (pCR) Rate — at surgery
ypT0 ypN0

Trial sites (1)

Facility	City	Region	Status
Renji Hospital, School of Medicine, Shanghai Jiaotong University	Shanghai	China

More Wenjin Yin trials in China

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer Recruiting

Trastuzumab Deruxtecan in Advanced Breast Cancer Recruiting

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer Recruiting

The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis Active, not recruiting

The Association Between Blood Routine Parameters and Breast Cancer Prognosis Active, not recruiting

Other trials for the same condition

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Active, not recruiting

Precision Regional Node Irradiation for Sentinel Node-positive Breast Cancer Active, not recruiting

Long-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial Recruiting

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer Recruiting

The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07590570 on ClinicalTrials.gov ↗ ← All trials in China